Section 02 — what got better in tests
Slow healing raises a fair question about TB-500 research.
A wound that stays open needs evidence beyond animal tests. Most used whole thymosin beta-4, leaving the small part's healing effects unknown.
What a 1:1 hold changes inside a cell
This test examined proteins with X-rays, rather than treating a wound in a person. Researchers saw thymosin beta-4 holding actin, a protein cells use to move [1]. The view reached 2 angstroms, a tiny unit of distance. The proteins joined 1:1: each protein held a single actin piece. Actin pieces can join into thin fibers that support a cell, but by holding both ends, thymosin beta-4 kept an actin piece from joining a fiber inside that cell. TB-500 contains the part that helps make this hold.
That leaves actin ready for cells to use as the cells change shape.
Cells need to change shape to move toward damage and build blood vessels. Those movements help tissue repair, but seeing the hold doesn't measure wound healing. If you're hoping a wound will close sooner, that remains unanswered by this X-ray test. The X-ray work studied the part while joined to the larger protein. The work didn't test TB-500 as treatment in your body.
What improved in mouse hearts but failed in pig hearts
These results concern the full protein tested in animals, so your heart may respond differently. In mice, thymosin beta-4 helped injured heart cells survive [2]. Heart cells and cells lining blood vessels moved toward damaged areas. Researchers tied a heart artery shut to cause the injury. After treatment, the hearts worked better and fewer heart cells died. The 2004 finding helped lead to further work on a possible heart medicine.
The pig results didn't show the same help.
In pigs, thymosin beta-4 failed to reduce injury after blocked blood flow returned. The mice and pigs show why animal findings can't settle your treatment choice. A later study of people after heart attacks finished without sharing results [10]. We don't know from that study whether the patients' hearts improved or whether treatment harmed anyone. The study used whole thymosin beta-4, rather than the short piece.
What TB-500 heart claims still cannot promise
Thymosin beta-4 improved mouse heart function after a heart artery was tied closed [2]. Giving thymosin beta-4 throughout the body didn't lessen pig heart injury after blood flow returned. The finished human heart-attack study of thymosin beta-4 hasn't shared findings about benefit or harm [10]. The seven-part piece has no human heart results to help you judge the claim.
What covered rat wounds with more new skin
These were deep rat wounds treated with whole thymosin beta-4, rather than human wounds. Comparison rats received salt water. Treated wounds grew 42% more skin at 4 days and up to 61% more at 7 days [3]. Thymosin beta-4 went on wounds or into the belly. Wounds shrank at least 11% more by day 7, with more collagen and blood vessels. Collagen helps give skin strength. In dish tests, 10 picograms, each equal to one trillionth of a gram, increased skin-cell movement two- to three-fold. These findings linked to TB-500 used the whole protein.
What TB-500 wound claims borrow from the whole protein
Whole thymosin beta-4 helped animal wounds close faster; eye-treatment studies also tested repair [3][5]. Findings included more skin, collagen, and blood vessels. A man-made actin-holding part shared some repair effects. Actin helps cells move. The review doesn't specify here which animal had which effect. That finding isn't human proof for the separated part.
Why TB-500 has no proved time to heal your wound
Your healing timetable still needs a human test. Rats treated with thymosin beta-4 grew 42% more skin at 4 days and up to 61% more at 7 days than rats receiving salt water [3]. Salt water was comparison treatment. Rat healing doesn't set your treatment times.
What TB-500 has yet to show for tendons and ligaments
Direct findings on thymosin beta-4 in tissues supporting joints are few [5]. Tendons join muscle to bone; ligaments keep joints together. Healing these tissues with the short part hasn't been proved in human studies.
What smaller amounts changed after rats had a stroke
These were male Wistar rats, a breed used for research, given whole thymosin beta-4. Belly shots used 2, 12, and 18 milligrams per kilogram the rats weighed. The first shot was 24 hours after stroke, with four further shots every 3 days. The 2 and 12 milligram-per-kilogram amounts improved movement and tests of brain function. Those tests checked how well rats used their bodies. Improvement held from day 14 through day 56. At 18 milligrams per kilogram, no clear help appeared [4]. A calculation suggested a best amount, without testing people.
More didn't mean better repair in these rats.
People trying the substance themselves sometimes describe starting with more, then using less. Those research-use accounts aren't controlled studies. The thymosin beta-4 rat results don't prove that approach for you.
Why brain repair with TB-500 still needs human proof
Rats improved with thymosin beta-4 at 2 and 12 milligrams for each kilogram the rats weighed [4]. At 18 milligrams per kilogram, no clear benefit appeared. A best amount was calculated, rather than tested in people. An earlier human heart-attack shot study ended before anyone joined [11]. That heart study supplies no stroke findings.
What repaired mouse muscle failed to change
Weak muscles after an injury can make you hope for a repair treatment. Rodent work used thymosin beta-4 to draw cells toward damaged muscle. Those cells could grow into new muscle, but more repair didn't always bring strength.
What TB-500 still needs to prove about getting stronger
A six-month test studied mice with an inherited muscle disease [5]. Thymosin beta-4 brought more muscle-forming cells toward injury and increased the fibers newly repaired in muscle. Yet the mice weren't stronger, their hearts worked no better, and scarring didn't lessen. For you, getting up from a chair matters more than counting repaired fibers. Human studies haven't checked TB-500 for recovery after exercise.
What TB-500 side effects still need human tests
Evidence about TB-500 side effects is scarce, and the human safety work used the larger protein. An early safety check called Phase 1 tested 40 healthy people [6]. Groups were picked by chance. One group received a placebo, treatment without the study drug, for comparison. Thymosin beta-4 went into a vein at 42, 140, 420, or 1260 milligrams. A single treatment was followed by daily treatment for 14 days. Mild or moderate unwanted effects were uncommon. No serious harm occurred, and harm didn't force treatment to stop. Higher amounts raised blood levels and took longer to clear.
A brief safety test can't tell you what happens after years of use.
Lab work finds more thymosin beta-4 in several cancers [5]. The protein encourages movement of cells and the growth of blood vessels, changes that could help repair tissue but might also help a tumor gain blood supply or spread. A 2026 review discussed TB-500 and thymosin beta-4 among substances without drug approval [12]. Repair findings in animals looked hopeful, but sound tests of human safety were few. The review raised concerns about serious harm and little oversight. Feeling fine today doesn't answer your question about harm years from now.
Why TB-500 raises a possible cancer risk
The concern rests on lab findings; cancer caused in users hasn't been proved [5]. Several cancers have more thymosin beta-4, with links to tumor growth and spread. A tumor might use the protein's effects to gain blood supply and spread cells. That possible risk hasn't been proved for people given the short part.
What TB-500 reports cannot tell you about shot safety
Your safety questions about the small piece still lack good human answers. Phase 1 testing found thymosin beta-4 well tolerated into a vein up to 1260 milligrams [6]. Growth of tumors remains a possible concern [5]. The contents of products intended for research may also differ from their labels.
Why TB-500 lacks an answer about years of safety
TB-500 hasn't had long safety tests in people. The longest controlled exposure was a 14-day Phase 1 test of thymosin beta-4 into a vein [6]. Possible tumor support through cell movement and blood supply remains unresolved [5][12]. You can't count a short test as proof about years of use.
What human studies can tell you when results are missing
The TB-500 piece has no finished human comparison study for treating illness [11]. Whole thymosin beta-4 has had human tests, but may act differently. In Phase 1, the protein was well tolerated into a vein up to 1260 milligrams [6]. A dry-eye study of thymosin beta-4 eye drops finished [7][9]. Finishing alone doesn't tell you whether symptoms improved. Separate work on eye tissue found less activity driving inflammation, the body's response to injury [8]. That tissue finding doesn't measure relief in people.
Missing results leave your questions about benefit and harm unanswered.
A later thymosin beta-4 study after human heart attacks finished without posted results [10]. An earlier shot trial for heart attacks stopped before enrolling anyone [11]. Neither tells you that the small piece has proved useful treatment. You need the findings, not just a study's finished status.
Which tests were of the full protein, leaving TB-500 untested
There aren't finished human comparison trials of TB-500. Thymosin beta-4 had a Phase 1 safety study with groups picked by chance [6]. Human work also tested thymosin beta-4 eye drops [7]. A later thymosin beta-4 heart-attack shot study completed, without results showing what happened to patients [10]. The earlier trial never treated anyone [11]. Your TB-500 treatment question can't rest on findings those trials haven't supplied.
What separates TB-500 and BPC-157 inside the body
Your comparison of TB-500 and BPC-157 begins with different substances, rather than similar healing claims. TB-500 matches part of thymosin beta-4, which helps cells move [1]. BPC-157 is a man-made chain of fifteen building blocks based on a protein present in the juices inside the stomach. That describes where the research began; it doesn't prove treatment for stomach trouble. The substances have different parts and act in different ways.
Neither has drug approval, and most findings come from animals. Both were on the July 2026 FDA advisers' agenda about pharmacy-made medicine [reg2]. Being discussed doesn't mean either substance is cleared for your care. The comparison gives you no tested reason to choose TB-500 or BPC-157.